JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 33 No. 5 724-734
© 1992 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, A.
Right arrow Articles by Katzenellenbogen, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, A.
Right arrow Articles by Katzenellenbogen, J. A.

Fluorine-18-Labeled Androgens: Radiochemical Synthesis and Tissue Distribution Studies on Six Fluorine-Substituted Androgens, Potential Imaging Agents for Prostatic Cancer

Aijun Liu, Carmen S. Dence, Michael J. Welch and John A. Katzenellenbogen

Department of Chemistry, University of Illinois, Urbana, Illinois
Division of Radiation Sciences, Mallinckrodt Institute, Washington University Medical School, St. Louis, Missouri

Correspondence: For reprints contact: John A. Katzenallenbogen, Department of Chemistry, University of Illinois, 461 Roger Adams Laboratory, Box 37, 1209 West California St., Urbana, IL 61801.

ABSTRACT

We have synthesized six androgens labeled with 18F as potential imaging agents for prostatic cancer. These include 16ß-fluorine-substituted testosterone, dihydrotestosterone and mibolerone, 16{alpha}- and 16ß-fluorine substituted 7 {alpha}-methyl-19-nortestosterone, and 20-fluoro-R1881 (metribolone). All of the radiochemical preparations proceeded in satisfactory yield, giving material with adequately high effective specific activity for the in vivo studies. In the tissue distribution studies in diethylstilbestrol-treated male rats, high selective uptake by the prostate was observed that ranged from 0.39% to 1.21% injected dose (ID)/g at 1 hr and 0.20 to 0.47 at 4 hr, with prostate-to-blood and prostate-to-muscle ratios ranging from 3.28 to 9.45, respectively, at 1 hr and 4.06 to 35.0, respectively, at 4 hr. Those compounds that are likely to be metabolized rapidly showed lower prostate uptake but higher uptake selectivity at 4 hr; at earlier times, uptake selectivities were more comparable. Compounds with a 16ß-fluorine substituent showed extensive metabolic defluorination, resulting in ca.50% of the dose being deposited in bone at 4 hr. This is consistent with a 16{alpha}-hydroxylation process that may proceed rapidly with these compounds, but would be retarded by a 17{alpha}-methylation, blocked by inversion of stereochemistry at C-16, and would not affect fluorine at the C-20 position. These fluoroandrogens, together with 20-fluoromibolerone described previously, are the first positron-emitting androgens to show high affinity and selective uptake by androgen target tissues in vivo, and they may be useful as in vivo prostate imaging agents in man.




This article has been cited by other articles:


Home page
JNMHome page
E. E. Parent, C. S. Dence, T. L. Sharp, M. J. Welch, and J. A. Katzenellenbogen
7{alpha}-18F-Fluoromethyl-Dihydrotestosterone and 7{alpha}-18F-Fluoromethyl-Nortestosterone: Ligands to Determine the Role of Sex Hormone-Binding Globulin for Steroidal Radiopharmaceuticals
J. Nucl. Med., June 1, 2008; 49(6): 987 - 994.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
P. B. Zanzonico, R. Finn, K. S. Pentlow, Y. Erdi, B. Beattie, T. Akhurst, O. Squire, M. Morris, H. Scher, T. McCarthy, et al.
PET-Based Radiation Dosimetry in Man of 18F-Fluorodihydrotestosterone, a New Radiotracer for Imaging Prostate Cancer
J. Nucl. Med., November 1, 2004; 45(11): 1966 - 1971.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
U. Scheffel and M. G. Pomper
PET Imaging of GRP Receptor Expression in Prostate Cancer
J. Nucl. Med., August 1, 2004; 45(8): 1277 - 1278.
[Full Text] [PDF]


Home page
JNMHome page
S. M. Larson, M. Morris, I. Gunther, B. Beattie, J. L. Humm, T. A. Akhurst, R. D. Finn, Y. Erdi, K. Pentlow, J. Dyke, et al.
Tumor Localization of 16{beta}-18F-Fluoro-5{alpha}-Dihydrotestosterone Versus 18F-FDG in Patients with Progressive, Metastatic Prostate Cancer
J. Nucl. Med., March 1, 2004; 45(3): 366 - 373.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1992 by the Society of Nuclear Medicine.